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Abstract: Background: Zinc is an essential nutrient for all forms of life and its deficiency affects the 
normal growth and development of human beings. Objective: The main aim was to investigate zinc 
nutritional status by serum zinc concentration (SZC) and dietary zinc intake and their association 
in cystic fibrosis (CF) patients. Methods: A cross-sectional study was conducted in CF patients. 
Anthropometric measurements and respiratory and pancreatic tests were conducted. 
Hypozincemia was determined by SZC while using atomic absorption spectrophotometry and 
dietary zinc deficiency by prospective 72-h dietary surveys. Results: Mean SZC (87.2 ± 16.7 μg/dL) 
and dietary zinc intake (97 ± 26.9% Dietary Reference Intake) were normal. Three of 17 patients 
with CF (17.6%) had hypozincemia and four (23.5%) had a dietary zinc deficiency. No patient with 
dietary zinc deficiency had hypozincemia. A positive and significant association was observed 
between SZC and Z-score of BMI-for-age (p = 0.048) and weight-for-height (p = 0.012) and between 
dietary zinc intake and energy intake (EI, p = 0.036) and Z-score of weight-for-high (p = 0.029). 
Conclusion: SZC was associated with the nutritional status, expressed as BMI (Body Mass Index) 
and weight-for-height Z score, and dietary zinc intake with EI and weight-for-height Z-score. No 
patient with hypozincemia had dietary zinc deficiency. This situation should alert us to a marginal 
zinc deficiency and it may explain why there were no overlapping cases between the two groups. 
We suggest that probably 41% of the cases in this study would be at elevated risk of zinc deficiency 
and a zinc supplementation may be considered. 
Keywords: serum zinc concentration; hypozincemia; dietary zinc intake; dietary zinc deficiency; 
cystic fibrosis; marginal zinc deficiency 
 
1. Introduction 
Cystic fibrosis is a chronic autosomal recessive disorder that affects the lungs and the digestive 
system of approximately 70,000 people worldwide and is caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene [1]. Nearly 2000 different disease-causing 
mutations have been identified, but the most common mutation (approximately 70% of patients) is a 
three-base-pair deletion (CTT) in exon 10. This mutation causes an in-frame deletion of a 
phenylalanine residue (DF508) and it results in the lack of a functional cAMP-gated chloride channel 
on the apical surface of secretory epithelial cells [2]. Thus, CF epithelia fail to transport chlorine and 
water, and morbidity in CF often results from lung disease [3]. The gastrointestinal manifestations of 
Nutrients 2019, 11, 150 2 of 18 
 
CF include exocrine pancreatic insufficiency and intestinal mucosal abnormalities [4]. The incidence 
of CF is about one in 3500 white births in Europe. The mean prevalence in the United States and de 
European Union (EU) is similar, 0.74 and 0.80 in 10,000 people, respectively [1]. Growth and 
development in patients with CF can be impacted by several factors that are associated with the 
disease, such as nutritional status and zinc in particular.  
The solution and complexation chemistry of zinc ions is the basis for zinc biology [5]. Zinc is a 
ubiquitous trace element [6,7]. Zinc is the 23rd most abundant element in the earth’s crust [8], having 
atomic number 30 and atomic weight 65.37, is vital in the living world [9]. Zinc is an essential trace 
element that participates in many metabolic processes as a catalytic, regulatory, and structural 
component [10]. It is a vital cofactor for the function of more than 10% of proteins that are encoded 
by the human genome (approximately 3000 proteins/enzymes) [11,12]). Zinc-dependent proteins 
play numerous indispensable roles within cells, such as transcriptional regulation, DNA repair, 
apoptosis, metabolic processing, extracellular matrix (ECM) regulation, and antioxidant defence 
[13]. It is also involved in the metabolic hormone regulation of growth and it has key roles in gene 
expression regulation and the immune system. Zinc also regulates thousands of genes through the 
metal response element (MRE) binding transcription factor-1 (MTF-1), and zinc controls numerous 
cell-signalling pathways by modulating kinase and phosphorylase activities. The coordination of 
these zinc-dependent cellular functions appears to be related to one or several of the 24 zinc 
transporters that exhibit differing specificity of expression in different cell types [14,15].  
Zinc is important for human health and disease due to its critical roles in growth and 
development [6,7], bone metabolism, the central nervous system, immune function, and wound 
healing [16]. Not only in physiological but also mental and behavioral terms [17]. Zinc is essential for 
a wide variety of cellular processes in all cells [18]. Cells with a rapid rate of turnovers, such as those 
of immune, gastrointestinal systems, and skin, are particularly vulnerable to zinc deficiency, 
accounting for the initial effects of dermatitis, diarrhoea, alopecia, and loss of appetite [19]. Zinc 
deficiency impairs both the specific susceptibility to bacterial, viral, and fungal pathogens [20]. This 
triggers an array of health problems in children, many of which can become chronic and serious, 
such as weight loss, stunted growth, weakened resistance to infections, and early death [21]. The 
early effects of zinc deficiency are chemical, functional, and may be “hidden”. Some examples of 
functions at risk are: gene expression, fetal growth and development, child and adolescent growth, 
wound healing, immunity, resistance to oxidative stress and inflammation, brain development, and 
neuropsychological function [22].  
Adequate zinc nutriture is critically important for human health [11]. Inadequate dietary intake 
of absorbable zinc is one of the major causes of zinc deficiency [23]. Zinc is a critical dietary nutrient, 
particularly in the early stages of life; epidemiological data suggest at least one in five humans is at 
risk of zinc deficiency [18]. It is present at less than 50 mg/kg in the human body [16]. At 2–3 g in 
total, zinc is the second most abundant metal in humans and it is distributed unequally throughout 
different organs and tissues. Prostate, pancreas, and bone are considerably high in zinc, containing 
up to 200 μg/g. In contrast, zinc concentrations in the heart, brain, and plasma are comparatively 
low, at 1–23 μg/g. Although plasma has only 1 μg/g, it is probably the most important reservoir for 
zinc homeostasis [24]. Zinc storage capacity seems to be highly vulnerable to reduced dietary intake 
or increased losses due to illness [25]. The concept of body zinc status is based on the notion of 
acquisition of zinc that is sufficient for optimal biological processes. This may be a consequence of 
dietary zinc intake, phytate consumption, gastrointestinal health, rate of zinc excretion and 
reabsorption, and other factors, many of which are not clear.  
Zinc deficiency can be both inherited and acquired [26,27]. Although severe zinc deficiency is 
extremely uncommon in European populations, marginal deficiency may be much more prevalent 
and is associated with immune system dysfunction and restricted physical development [28]. 
Marginal zinc deficiency is characterized by slight weight loss, rough skin, oligospermia, and 
hyperammonemia [24,29]. The clinical signs of marginal zinc deficiency include a decrease in 
immunity, taste and smell senses, night blindness, memory compromise, and decreased 
spermatogenesis [29]. Clinical diagnosis of marginal zinc deficiency in humans remains problematic. 
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Acquired deficiency of zinc has now been reported in many diseases, such as cirrhosis of the liver, 
chronic renal disease, malabsorption syndrome, chronic alcoholism, sickle cell disease, and other 
chronic diseases, including malignancies [30]. WHO (World Health Organization)/UNICEF (United 
Nations International Children's Emergency Fund)/IAEA (International Atomic Energy 
Agency)/IZiNCG (International Zinc Nutrition Consultative Group) bodies recommend the use of 
three indicators to value zinc status at the population level: prevalence of intakes below the 
estimated average requirement, percentage of low serum zinc concentration, and percentage of 
children less than five years who are stunted [31,32]. There are four main intervention strategies for 
combating zinc deficiency, which include dietary modification/diversification, supplementation, 
fortification, and bio-fortification [11].  
The overall goal in CF is that every patient should achieve normal growth. In CF patients, zinc 
deficiency can be common due to disturbed protein intake and fat malabsorption [33]. Zinc 
deficiency can lead to a broad range of consequences [34] and symptoms, such as stunted growth, 
delayed sexual maturation, disturbed immunity, poor appetite, and diarrhoea, each of which is 
frequently present in patients with CF [35]. Young infants, because of their rapid growth rate, have 
relatively high physiologic zinc requirements [36]. Approximately 35% of the children with CF aged 
between five and 10 years were either nutritionally ‘at risk’ or in ’urgent need’ of nutritional 
intervention and rehabilitation. CF patients are at risk of zinc deficiency, which is a manifestation of 
steatorrhea [37]. Damphousee et al. point out that almost a quarter of adults with cystic fibrosis who 
had a good nutritional status had a low plasma zinc concentration, and those with a low plasma zinc 
concentration had a poor clinical outcome [38].  
Zinc is involved in many metabolic and chronic diseases, such as: diabetes, cancer 
(oesophageal, oral small cell carcinoma, breast cancer), and neurodegenerative diseases. There is 
also strong evidence between zinc deficiency and several infectious diseases, such as malaria, HIV 
(human immunodeficiency virus), tuberculosis, measles, and pneumonia [39]. At the moment, the 
real extent of the prevalence of zinc deficiency in the world is unknown, and we have nothing more 
than a very rough estimate not only of the prevalence, but also of the potential impact on global 
health that can be expected from improving zinc nutrition in populations [40]. The partial ignorance 
of zinc deficiency as a public health problem makes it necessary to carry out studies to know more 
about zinc nutritional status in CF patients. Therefore, the main aim of the study was to evaluate 
zinc status in CF patients by assessing their SZC and dietary zinc intake.  
2. Materials and Methods 
A cross-sectional study was conducted including both paediatric and adult CF patients with 
homozygous Delta F580 and other related mutations, which were consecutively referred for 
nutritional assessment to the Paediatrics service at the University Clinical Hospital of Valladolid, in 
a period of 18 months. The local ethics committee at the University Clinical Hospital reviewed and 
approved this study. Anthropometric assessment (weight, height) using standard techniques and 
Z-score of weight-for-age, height-for-age, weight-for-height, and BMI were calculated using 
Orbegozo Tables [41]. The growth rate of CF patients was calculated by using clinical history data. The 
Score Norman-Crispin (>5), forced vital capacity (FVC% < 80%), and forced expired volume in 1 s 
(FEV1 < 80%) predicted value by spirometry to estimate respiratory-insufficient (RI), and the 
coefficient fat-absorption (CFA > 94%) by 72-h quantitative faecal fat collection to value 
pancreatic-sufficient (PS) and insufficient (PI) were realized. All patients were treated with 
pancreatic enzyme replacement therapy (PERT) and fat-soluble vitamin supplements (Table 1).  
Fasting blood samples were collected and all research procedures minimized the risk of 
contamination. The SZC was conducted at Chemistry Department of the University of Valladolid 
using an atomic absorption spectrophotometer (model PU9400 Philips) [42]. Serum zinc <70 μg/dL 
in children <10 years of both sexes and in women aged ≥10 and <74 μg/dL in men aged ≥10 were 
used as cutoff to evaluate hypozincemia [31]. We examined the activity of acute phase proteins as 
inflammatory markers, including C-reactive protein (CRP) > 4 U/L and erythrocyte sedimentation 
rate (ESR) woman > 20 mm/h, men > 15 mm/h, by standardized methods. Diet analysis was made 
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through a prospective dietary survey of 72 h (including one of the weekend days). From that, daily 
EI (calories) and dietary zinc intake based on estimated portions and referred for the percentage of 
Dietary Reference Intake (%DRI) was assessed using the Mataix Food and Health computer program 
[43]. In order to assess inadequate dietary zinc intake, we used the cut point <80%DRI.  
The marginal or subclinical zinc status is defined as a deficit state without pathognomonic 
clinical signs and with an acceptable (normal values) SZC in patients with dietary zinc deficiency 
[44]. The risk of zinc deficiency by height-for-age of growing infants and children (>20% of stunting), 
dietary zinc intake (>25% of dietary zinc deficiency), and SZC (>20% of hypozincemia) was used to 
estimate zinc status (Figure 1). Data are expressed as mean ± standard deviation score (SDS), 
median, ranges, and percentages. Differences between normal and deficient groups with nutritional 
status variables were assessed using unpaired Student t-tests or Wilcoxon rank tests for 
non-normally distributed variables. Pearson correlation coefficients were performed to test for 
significant associations among the same variables. The significance level was set at p < 0.05. Analyses 
were performed using the SPSS/PC software (IBM Corp., Armonk, NY, USA). 
 
Figure 1. Graphic of design of the cross-sectional study to value the risk of zinc deficiency. 
Table 1. Baseline Characteristics of the Subjects (N = 17 *). 
Characteristics Mean ± SD or No. (%) Median Range 
Female (%) 10 (58.8%)   
Male (%) 7 (41.2%)   
Age (years) 14.8 ± 8 15 2–31 
Sick time (months) 159.7 ± 85 148 29–298 
Genotype (%) (n − 17)    
CYSTIC FIBROSIS
Proven diagnosis and signed informed consent
EXCLUDED
Acute infection, hospitalization 
and abandoment
INCLUDED 
NUTRICIONAL SURVEY
ANTHROPOMETRIC 
ASSASSMENT
(weight, height)
CHILDHOOD STUNTING
Height-for-age Z-score 
<2 SD in children <5 years
> 20%
Stunted growth 
PROSPECTIVE DIETARY SURVEY
of 72 h (including one of the 
weekend days)
DIETARY ZINC DEFICIENCY
< 80% of Dietary Reference 
Intake to zinc intake
>25%
Dietary zinc deficiency 
BLOOD ANALYTICAL
Serum zinc concentration by flame 
atomic absorption spectrophotometry
HYPOZINCEMIA
≤ 70 µg/dL in children <10 years of 
both sexes and in women aged ≥ 10 
≤74 µg/dL in men aged ≥10
>20%
Hypozincemia
RESPIRATORY AND PANCREATIC FUNCTION
Score Norman-Crispin >5 
Forced Vital Capacity <80%
Forced Expired Volume in 1 s < 80%  
Coefficient fat-absorption > 94%   
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Homozygous ∆F580 6 (35.3%)   
Heterozygous ∆F508 7 (41.2%)   
Other mutations 4 (23.5%)   
Management    
Lipase (IU/kg/day) 4881 ± 1469 5000 14500–7200 
Vitamin A (IU) 5500 ± 3438 5000 0–10000 
Vitamin E (IU) 223 ± 137 200 0–420 
Vitamin D3 (IU) 578 ± 360 666 0–1333 
Vitamin K (mg/w) 9.5 ± 4.3 10 0–20 
Respiratory and Pancreatic Function    
Forced Vital Capacity (%) 83.9 ± 38.1 78.8 33–198 
Forced Expired Volume in 1 s (%) 79.2 ± 25.8 78.9 29–129 
Score Norman-Crispin 6.3 ± 5.5 6.5 0–19 
Coefficient fat-absorption (%) 88.4 ± 8.6 91.3 72.3, 100 
Nitrogen Balance 3.7 ± 5.3 2.8 −6.4–11.4 
Anthropometric Assessment    
Body Mass Index (Kg/m2) 17.4 ± 2.6 16.3 14.2–23.4 
Body Mass Index Z-score −0.95 ± 1.1 −0.6 −3.8–0.6 
Weight (kg) 37.9 ± 15.4 36.7 10.7–60.4 
Height (cm) 143.9 ± 24.4 154.8 85–169.9 
Weight-for-age Z-score −1.2 ± 1.1 −1.3 −2.9–0.4 
Height-for-age Z-score −0.6 ± 1.1 −1.2 −1.9–0.92 
Weight-for-height Z-score 0.22 ± 1.51 0.1 −1.4–4.58 
Growth rate (cm/year) 5.12 ± 2.3 5.5 0.19–7.56 
Blood Analytic    
Serum Zinc level (μg/dL) 87.2 ± 16.7 86 58–122 
C-reactive protein (u/L) 4.6 ± 2.4 3.7 3.1–12 
Erythrocyte sedimentation rate (mm/h) 13.1 ± 5 12 6–23 
C-reactive protein (>4 u/L) 3 (17.7%)   
Erythrocyte sedimentation rate * 2 (11.8%)   
Prospective Dietary Survey    
Dietary zinc intake (%DRI) 97 ± 26.9 98.2 54.9–153.9 
Zinc intake (mg/day) 14.5 ± 4 14.7 8.2–23.1 
Energy intake (calories) 2594.9 ± 464.5 2672.4 1846–3409.6 
Comorbidities (%)    
Undernutrition 5 (29.4%)   
Hypozincemia (μg/dL) 3 (17.6%)   
Dietary zinc deficiency (%DRI) 4 (23.5%)   
Respiratory insufficiency 9 (52.9%)   
Pancreatic insufficiency 13 (76.5%)   
* 17 cystic fibrosis patients were screened, included and analysed. No patients were excluded. 
Abbreviations: %DRI: Percentage of Dietary Reference Intake. * woman > 20 mm/h, men > 15 mm/h. 
IU: International Units. Vitamin D3: Cholecalciferol. 
3. Results 
In this cross-sectional study, seventeen CF patients (10 females, seven males) were studied, and 
their characteristics are summarized in Table 1. The mean age was 14.8 ± 8 years with median 15 and 
range was 2–31 years (seven children, five adolescents and adults). Seven CF patients have 
homozygous Delta F580, and other six patients have other CFTR mutations. The genotype of cystic 
fibrosis subjects was elaborated by Biological and Molecular Genetics of the School of Medicine at 
Valladolid University (Table 2). The 29.4% (5/17 cases) were malnourished (BMI < −2SDS). The 64.7% 
of CF patients had RI (mean Score Norman-Crispin 6.3 ± 5.5 and FEV1 77.7 ± 26.1%) and 94.1% PI 
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(mean coefficient fat-absorption 88.4 ± 8.6%). The nitrogen balance was positive but lower (mean 
was 3.7 ± 5.3). There was no significant difference in weight-for-age, height-for-age, 
weight-for-height, and BMI Z-score, according to gender, pancreatic, and pulmonary function. 
However, PS patients had less BMI than PI patients (p = 0.020). No patients had stunted growth. The 
growth rate in patients with hypozincemia was normal; only one patient with IP had a growth rate 
that slightly decreased. The median FEV1 was 78.9% and FVC% was 78.8%. There were 17.6% of 
patients colonized with Pseudomonas aeruginosa, Candida spp, and 23.5% by Staphylococcus aureus. 
Their lung function was not a significantly worse than those without such colonisation (Table 3). 
There were 13 patients (76.5%) with steatorrhea and nine (52.9%) with respiratory insufficiency. 
Weight-for-age was not affected by IP and was normal in patients with zinc deficiency intake.  
Table 2. Genotipe of fibrosis cystic patients. 
Genotipe of Fibrosis Cystic Patients Number 
Delta F-508 homozygous 8 
Delta F508/2183AA → G 2 
Delta F-508 mutation in intrón 12 (1898 +1G → A) 1 
Delta F-508/1717-IG-A 1 
Delta F-508/S549R 1 
Mutation 1717-1G 1 
Mutation 1341-A → G exon 8 1 
Mutation G → A exon 8, G673X exon 13 1 
Mutation L97F exon 17 1 
Total 17 
Table 3. Differences between fibrosis cystic patients. 
Characteristics Male Female p-Value 
Age (years) 10.4 ± 7.2 17.2 ± 7.9 0.091 
Serum zinc concentration (μg/dL) 93.3 ± 10.2 83 ± 19.5 0.223 
Dietary zinc intake (mg/day) 12.8 ± 3.9 15.9 ± 3.8 0.142 
Dietary zinc intake (%DRI) 85.6 ± 25.9 105.9 ± 25.5 0.140 
Colonisation Yes No t-value 
FVC 76.9 ± 24.2 94.5 ± 53.7 0.478 
FEV1 74.9 ± 27.3 84.9 ± 27.5 0.511 
Respiratory function Sufficient Insufficient t-value 
Serum zinc concentration (μg/dL) 90 ± 16.6 84.8 ± 17.4 0.537 
Dietary zinc intake (%DRI) 81.5 ± 20.8 112.5 ± 23.6 0.015 
Pancreatic function Sufficient Insufficient t-value 
Serum zinc concentration (μg/dL) 82 ± 1204 88.8 ± 17.9 0.417 
Dietary zinc intake (%DRI) 103.2 ± 11.4 95.6 ± 29.5 0.484 
FVC: forced vital capacity; FEV1: forced expired volume in 1 second;  
%DRI: Percentage of Dietary Reference Intake. 
The mean SZC of 87.2 ± 17 μg/dL and it ranged between 58 and 122 μg/dL. Although males had 
a higher SZC (93.3 μg/dL) than females (83 μg/dL), it was not significant. The mean BMI and 
weight-for-height Z-score SDS was −0.95 ± 1.1 and 0.22 ± 1.51, respectively. There was a positive 
correlation between SZC and BMI Z-score (r = 0.49; p = 0.048) (Figure 2), and weight-for-height 
Z-score (r = 0.59; p = 0.012) (Figure 3). CRP and ESR levels were normal except in three (17.7%) and 
two patients (11.9%), respectively. ERS and CRP were slightly increased in a single patient with 
hypozincemia (23 mm/h) and zinc intake deficiency (6.9 U/L), respectively. The mean of dietary zinc 
intake was 97 ± 26.9%DRI (14.5 ± 4 mg/day) and it ranged between 54.9 and 153.9% (8.2–23.1 
mg/day), and EI was 2594.9 ± 464.5 and ranged between 1846 and 3409.6 kcal. Females had a higher 
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dietary zinc intake (105.8%) than males (85.6%), although males (2631.1 Kcal) had an insignificantly 
higher than females (2566.9 Kcal). There was a positive correlation between dietary zinc intake and EI 
(r = 0.53; p = 0.036) (Figure 4), and weight-for-height Z-score (r = 0.55; p = 0.029) (Figure 5). There was 
no significant difference in SZC by respiratory and pancreatic function. Conversely, patients with RI 
had dietary zinc intake that was significant higher than normal patients (t = 0.015) (Table 3). 
 
Figure 2. Relationship between serum zinc concentration and Body Mass Index Z-score. 
 
Figure 3. Relationship between serum zinc concentration and weight-for-height Z-score. 
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Figure 4. Relationship between dietary zinc intake and energy intake. 
%DRI: Percentage of Dietary Reference Intake. 
The analysis showed that there were 17.6% of CF patients with hypozincemia, 23.5% with 
dietary zinc deficiency, and no patients under five years old had growth stunted. Three 
women—one infant eutrophic DF508/2183AA-G, one adolescent, and adult malnourished DF508 
homozygous—had hypozincemia. Four patients had a dietary zinc deficiency, three-male—one 
infant eutrophic DF508 with a mutation in intron 12 (1898 + 1G → A), one adolescent malnourished 
DF508/1717-1G, and one adult eutrophic DF508/S549R—and one-woman adult eutrophic DF508 
homozygous. No patient with dietary zinc deficiency had hypozincemia. 
4. Discussion 
There is a strong plausibility for zinc deficiency in infants and children with CF. Zinc deficiency 
has been documented in young infants identified by newborn screening prior to the initiation of 
pancreatic enzyme therapy [4]. In settings without newborn screening, the presentation is typically 
later in infancy, with associated growth faltering, diarrhoea, and dermatitis similar to acrodermatitis 
enteropathica [45]. Investigators have examined the relationship between zinc, body composition, 
growth, and pulmonary function in older children and adults with CF after the original report by 
Halsted and Smith in 1970 [46]. Nowadays, the use of zinc-finger nucleases to permanently and 
precisely modify the human genome offers a potential alternative to cDNA-based gene therapy in 
subjects with CF [2]. In Spain and in the EU there are few studies of zinc nutritional status in CF 
patients. Therefore, the main aim of the present study was to evaluate zinc nutritional status in CF 
patients by determining the percentage of cases with hypozincemia, stunted growth in children less 
than five years and inadequate dietary zinc intake.  
Zinc, an almost omnipresent metal ion, is not only a vital element in various physiological 
processes but also a drug in the prevention and management of many diseases. Nearly half of the 
world’s population is at risk for inadequate zinc intake, suggesting that public health programs are 
urgently needed to control zinc deficiency. The inability to link the physiological effects of zinc 
depletion to zinc status is due, in part, to an incomplete understanding of the biochemical and 
physiologic functions of zinc [10]. Zinc’s anticopper action is unique [47]. A moderate level of zinc 
deficiency has been observed in many gastrointestinal disorders. These include malabsorption 
syndrome, Crohn’s disease, regional ileitis, and steatorrhea. In 1968, MacMahon et al. [48] were the 
first to report zinc deficiency in a patient who had steatorrhea. Zinc deficiency in patients with 
malabsorption syndrome is now well recognized, and most physicians are aware of this problem 
[49].  
The lack of generally accepted biomarkers of zinc status has further impeded the estimation of 
the global prevalence of zinc deficiency [47]. No single body zinc compartment represents an 
adequate estimate of overall body zinc status [31,32]. The normal concentration of zinc in human 
blood serum and urine (24 h) is 800 ± 200, 109 to 130, and <500 μg/dL, respectively. The mean serum 
zinc concentration is 1 mg/L [50]. Red blood cells contain about 10 times higher concentration than 
that in the serum. Whole blood has about five times the serum concentration [51]. A thorough 
assessment of zinc status by current methods is complex. For now, the simplest measure is plasma 
zinc, which is 71% sensitive for clinically apparent deficiency [25], at a cutoff of 40 mg/dL [52]. It is 
insensitive for marginal (subclinical) deficiency. Thus, it is difficult to identify zinc deficiency in 
association with acute diarrhoea and to know how to monitor efficacy of replacement in terms of 
zinc nutrition [7].  
A sensitive, specific biomarker of zinc nutrition has not been identified for the individual 
diagnosis of zinc deficiency. The most commonly used measurement of zinc status is plasma or 
serum zinc, despite the fact that less than 0.1% of body zinc is present in plasma and the 
concentration appears to be under strict homeostatic control. Despite these limitations, the fact that 
plasma zinc concentrations are normally distributed in healthy populations makes it possible to 
establish reference values to be used to identify individuals at risk for a low zinc status [53]. 
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Therefore, plasma or serum zinc concentration is the only biochemical indicator to assess the zinc 
status of populations recommended by WHO/UNICEF/IAEA/IZiNCG [31]. 
In spite of the fact that the number of CF patients in the study is small, we must take into 
account that the results show that median SZC (86 μg/dL) in this series was normal and 17.6% of 
patients had hypozincemia. The median did not differ significantly from the National Health and 
Nutrition Examination Survey (NHANES) II study (88 μg/dL) [31]. In a study of 30 children with CF 
(mean age 8.65 ± 3.01 years) in a Children’s Medical Centre in Tehran, the mean SZC was 111.43 
μg/dL, which is significantly higher than results in age-matched controls (91.43 μg/dL, p < 0.00) [33]. 
Ataee et al. found that CF patients had 29.4% malnourished, 94.1% PI, and 64.7% RI [33]. This is in 
contrast to the present study, where only two women (11%) with hypozincemia—one adolescent 
and adult—were malnourished (mean BMI − 2SDS), and the adolescent had PI (fat absorption 
coefficient 91.74%) and RI (FEV1 52%). Maqbool et al. proved an association between suboptimal 
plasma zinc, poor nutrition, and growth status in infants with CF and PI. Growth faltering observed 
in older children with CF is undoubtedly multifactorial, including malnutrition, however, in one 
report older children’s total dietary zinc intake and zinc status were adequate and unrelated to 
growth status [54].  
Borowitz et al. point out that hypozincemia in CF is difficult to characterize, because zinc 
deficiency may be present when plasma zinc is in the normal range [55]. In a study, increased zinc 
loss in 101 patients (mean age 16 years) with persisting steatorrhea was found, and 12.6% of this 
population had SZC below the p-value of 2.5 of the NHANES II, so there could have an increased 
risk of zinc deficiency in some CF patients [56]. Although hypozincemia has been reported in 
approximately 30% of young infants with CF in newborns screenings [33], Maqbool et al. reveal that 
prevalence of low plasma zinc ranging from 0% to 40% in various populations of infants, children, 
and adolescents with CF [54]. There have been several reports of young infants with CF presenting 
with signs and symptoms of severe zinc deficiency [36], such as growth retardation, increased 
susceptibility to infections, delayed sexual maturation, eye problems, and anorexia that are caused 
by a reduced sense of taste (hypogeusia) [1].  
In this study, no patient had growth stunted. The growth rate in these patients with CF and 
hypozincemia was normal. Only one patient with IP had a growth rate slightly decreased. Up to 
now, no studies have been able to demonstrate a relation between serum zinc and growth 
parameters. However, the decrease in insulin-like growth factor 1 (IGF-1) concentrations correlate 
with the nutritional status of CF patients. Zinc supplements could theoretically have beneficial 
effects on energy expenditure, appetite, nutritional status, as well as growth. Only one retrospective 
study examined and demonstrated an improved EI during zinc supplementation in CF patients with 
low serum zinc. CF patients may theoretically benefit from zinc supplements in several different 
aspects of their disease. A retrospective analysis of clinical data suggests improved appetite, EI, 
nutritional status, as well as pulmonary function with zinc supplements [37]. Van Biervliet et al. 
show that high-dose (5 mg zinc/kg/day) supplementation was associated with beneficial effects on 
growth and pulmonary function [57]. However, no controlled trials are available that replicate these 
effects.  
However, many studies have shown that zinc plays a role in promoting physical growth and 
the development of intelligence in children [58]. Young children are at greater risk of zinc deficiency 
because of increased zinc requirements during growth. Exclusively breastfed infants of mothers 
with adequate zinc nutriture obtain sufficient zinc for the first 5–6 months of their life [59]. Children 
are particularly sensitive to a suboptimal state of zinc during periods of rapid growth that create a 
higher need for zinc that may not be met [60]. It seems to be that zinc is the most important factor in 
the needs related to the deposit of new tissue, since 20 mg of zinc are needed for each kg of muscle 
mass [61]. Therefore, a higher growth rate corresponds to higher net zinc retention [62]. After this 
age, complementary foods containing absorbable zinc are required to satisfy their requirements. The 
physiological requirements for zinc peak during adolescence at the time of the pubertal growth 
spurt, which generally occurs in girls between 10 years and 15 years and in boys between 12 years 
and 15 years. Even after the growth spurt has ceased, adolescents may require additional zinc to 
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replenish depleted tissue zinc pools [63]. On the other hand, a marginal zinc status during the 
outbreak of pubertal growth has been associated with slow skeletal growth, maturation, and 
reduction in bone mineralization [31].  
Recent studies have demonstrated that a well-balanced diet leads to an improved redox status, 
which positively affects reducing the risk of non-communicable chronic diseases [64]. An inadequate 
intake of micronutrients at any stage of life affects various functions within the immune system, 
manifesting in decreased resistance to infections and an increase in the severity of symptoms. For 
example, zinc deficiency can increase thymic atrophy, decrease lymphocyte number and activity, 
and increase oxidative stress and inflammation by altering cytokine production [65,66]. As a result, 
the risk of all types of infection (bacterial, viral, and fungal), but especially diarrhoea and 
pneumonia, is increased [67].  
In this study, the median dietary zinc intake for CF patients (98%DRI) was normal and 23.5% of 
them had dietary zinc deficiency with less than 80%DRI and approximately 5.9% exceeding the 
upper level (UL). Median dietary zinc intake in this study was significantly lower than the NHANES 
II control group (178% Recommended Dietary Allowance) (p < 0.00) [68], and did not differ 
significantly from the ANIBES study (83%). ANIBES (Anthropometry, Intake, and Energy Balance in 
Spain) was a Spanish study that evaluates energy intake and expenditure, body composition, and 
dietary patterns in a national representative sample of subjects. The subjects that were excluded 
from the study were those that were on a prescribed diet due to medical tests, pre- or post-surgery 
situation, diagnosed disease or any pathological or physiological situation, or those with any disease 
or illness (e.g., cold, gastroenteritis, chicken pox, etc.). Here, Olza et al. show that the percentage of 
the Spanish population included in the ANIBES study, as in this study, not meeting the European 
recommendations for zinc. Even when the plausible energy reporters were analysed separately, 
these percentages remained above 40% [69]. 
In spite of the fact that 23.5% of patients had inadequate dietary zinc intake, none of them had 
hypozincemia (17.6%). Low serum zinc concentrations can occur in the presence of several 
conditions, representing a normal physiologic response and they are not necessarily indicative of 
low zinc status [11]. Zinc can be temporarily redistributed from plasma to other tissue or the 
concentrations can be changed by conditions that are unrelated to zinc status. Infections, fever, food 
intake, and pregnancy lower plasma zinc, whereas starvation and catabolism increase it. Plasma zinc 
is also depressed at times of rapid tissue growth [70]. Cellular, tissue, and whole-body zinc 
homeostasis are tightly controlled to sustain metabolic functions over a wide range of zinc intakes, 
making it difficult to assess zinc insufficiency or excess [71]. In many moderate zinc dietary 
restrictions (3–5 mg/day), the response is more inconsistent, with a slight decrease or no change in 
serum zinc concentrations, possibly related to the duration of the dietary restriction and the 
relationship phytate:zinc molar ratio from the diet. Serum zinc levels fall clearly when the dietary 
zinc intake is less than approximately 2 to 3 mg, reaching a plateau when zinc intake reaches 
approximately 25 to 30 mg/day [31]. This means that, in populations with a high prevalence of 
inadequate zinc intake, there would be a higher prevalence of low serum zinc concentration [72]. 
Thus, the prevalence of low concentrations of serum zinc may be indicative of the risk of zinc 
deficiency in the population [31,40]. It is striking that, in spite of this fact, no more cases of 
hypozincemia will be presented in this study.  
A retrospective study in 304 adults CF patients with good nutritional status and moderate lung 
disease reported that one-fifth of them (22.4%) were deficient in zinc (<60 μg/dL), regardless of their 
nutritional status, as BMI was not found to differ significantly between zinc deficient and sufficient 
patients [38]. This is in contrast to the present study, where SZC was associated with nutritional 
status, expressed as BMI Z-score (p = 0.048) and weight-for-height Z-score (p = 0.012), and dietary 
zinc intake with EI (p = 0.036) and weight-for-height Z-score (p = 0.029). These data suggest that zinc 
is likely to be a growth-limiting factor in this group of CF patients, which is mainly due to an 
acquired deficiency of zinc secondary to its inherited chronic disease, which increases the losses of 
zinc by steatorrhea. There was no significant difference in anthropometric, as assessed according to 
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gender, pancreatic, and pulmonary function, except for lower BMI in patients with PS than PI 
patients (p = 0.002).  
Those observations are not surprising, because the gastrointestinal manifestations of this 
common heritable condition include exocrine pancreatic insufficiency and intestinal mucosal 
abnormalities [54], which produces malabsorption of essential fatty acids, fat-soluble vitamins, and 
several micronutrients, including zinc [73]. Increasing evidence demonstrates the importance of zinc 
in CF-affected tissues including the lungs and pancreas [38]. Zinc is particularly abundant in the 
pancreas, where it is involved in the control of glucagon secretion and digestive enzyme activity. 
Zinc is very important in the synthesis, storage, and secretion of insulin, as well as in maintaining 
conformational integrity of insulin in the hexameric form. Any decrease in zinc levels can affect the 
ability of the islet of Langerhans cell to produce and secrete insulin, and compound the problem, 
particularly in type II diabetes [74]. Therefore, zinc deficiency is associated with decreased insulin 
secretion and sensitivity, features that are characteristic of CF-related diabetes [38].  
It should be understood that the major organ system of zinc exchange with the environment is 
the gut [25,36]. The current understanding of zinc homeostasis indicates that the primary 
determinants of zinc absorption are the amount of zinc ingested and dietary phytate, with the latter 
having a major effect on zinc bioavailability. However, in normal as well as in many pathologic 
conditions, the gastrointestinal tract is the major site of zinc losses resulting from the secretion of 
endogenous zinc into the lumen and subsequent excretion in the faeces [44]. Zinc is primarily 
absorbed by a saturable process in the proximal small bowel but also more distally through 
entero-enteric reabsorption that diminishes losses [75]. Two generalized dietary patterns are major 
factors in the aetiology of dietary zinc deficiency; one in which the inhibition of absorption 
predominates and bioavailability is the issue and the other in which the zinc content of the diet is 
deficient [76]. The adjustments in gastrointestinal zinc absorption and endogenous excretion are 
synergistic. Shifts in the endogenous excretion appear to occur quickly with changes in intake just 
above or below optimal intake, while the absorption of zinc responds more slowly, but it has the 
capacity to cope with large fluctuations in intake [77]. With extremely low zinc intakes or with 
prolonged marginal intakes, secondary homeostatic adjustments may augment the gastrointestinal 
changes. These secondary adjustments include changes in urinary zinc excretion, a shift in plasma 
zinc turnover rates, and possibly, an avid retention of zinc released from selected tissues, such as 
bone, in other tissues to maintain function [78,79]. 
The results showed that some participants still had residual steatorrhea (76.5%), even though all 
patients except one of them received adequate doses of PERT and fat-soluble vitamins supplements 
with their diet. The correlation between dietary zinc intake and weight-for-height Z-score was not 
influenced in the absence of residual steatorrhea. Therefore, patients without PI had a normal 
weight-for-age Z-score, and there was no correlation significant between them and dietary zinc 
intake. On the contrary, weight-for-height Z-score had a positive and significant correlation with 
dietary zinc intake (r = 0.58, p = 0.038) in patients with PI. Weight-for-age was not affected by IP and 
it was normal in patients with zinc deficiency intake.  
Pancreatic insufficiency is frequently present in CF and it causes a major problem for zinc 
absorption. The fact that zinc deficiency increases the susceptibility to childhood diarrhoea while 
increased losses of endogenous zinc that are associated with diarrhoea further deplete body zinc, 
resulting in a vicious cycle that merits further study [80]. Recent stable isotope studies have reported 
increased endogenous faecal zinc losses and decreased zinc absorption in children and infants with 
CF [44,55]. Untreated pancreatic insufficiency also increases zinc losses. The fractional zinc 
absorption is improved by PERT. However, some CF patients continue to have steatorrhea despite 
correct PERT, and might, therefore, be at risk for developing zinc deficiency. Many CF patients have 
a suboptimal nutritional status despite the nutritional advice and PERT [37]. For infants and children 
<2 years of age who are not growing despite apparently adequate nutritional intake, a six-month 
trial of zinc supplementation (1 mg zinc/kg/day) has been recommended [55].  
Despite treatment with supra-physiological doses of pancreatic enzyme supplements, residual 
steatorrhoea is a common problem in patients with cystic fibrosis (CF) and pancreatic insufficiency. 
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Strategies to enhance the activity of pancreatic enzymes include decreasing duodenal acidity. 
Proesmans and Deboec evaluated the effect of omeprazole (Losec), a proton-pump inhibitor, on fat 
absorption in 15 CF patients (three girls and 12 boys) with confirmed residual steatorrhoea, despite a 
high dose pancreatic enzyme supplements (Lipase > or =10,000 UI/kg/day). During treatment with 
omeprazole, median faecal fat loss (g fat/day) decreased from 13 g (quartiles 11.5–16.5 g/day) to 5.5 g 
(quartiles 4.9–8.1 g/day) (p < 0.01). The same improvement was noted when fat absorption was 
calculated: 87% (quartiles 81–89%) without versus 94% (quartiles 90–96%) with omeprazole (p < 
0.001). They concluded that omeprazole improves fat digestion and absorption in CF patients with 
residual faecal fat loss despite maximal pancreatic enzyme substitution [81]. This improvement 
could contribute to an increase in zinc absorption. However, suppression of gastric acid secretion by 
omeprazole reduces intestinal absorption of zinc in other studies [82,83]. Farrel et al. point out that 
PPI use dramatically reduces supplemental zinc uptake and it can result in decreased zinc body 
stores. Certain individuals on long-term PPI therapy, such as infants being treated for colic, may be 
at risk for decreased systemic levels of trace metals that are needed for developmental, regenerative, 
and immunological requirements [83]. 
The participants were clinically stable at the time of the study. ERS and CRP were slightly 
increased in a single patient with hypozincemia (23 mm/h) and zinc intake deficiency (6.9 U/L), 
respectively. C-reactive protein (CRP) is an acute-phase protein that serves as an early marker of 
inflammation or infection. The protein is synthesized in the liver and it is normally found at 
concentrations of less than 10 mg/L in the blood. During infectious or inflammatory disease states, 
CRP levels rise rapidly within the first 6 to 8 h and peak at levels of up to 350–400 mg/L after 48 h. 
CRP binds to phosphocholine expressed on the surface of damaged cells, as well as to 
polysaccharides and peptosaccharides that are present on bacteria, parasites, and fungi. This 
binding activates the classical complement cascade of the immune system and modulates the 
activity of phagocytic cells, supporting the role of CRP in the opsonization (i.e., the process by which 
a pathogen is marked for ingestion and destruction by a phagocyte) of infectious agents and dead or 
dying cells. When the inflammation or tissue destruction is resolved, the CRP levels fall, making it a 
useful marker for monitoring disease activity [84]. Elevated concentrations of C-reactive protein or 
other markers of the acute phase response can be used to indicate the presence of infection and 
should be considered in the interpretation of results [85]. 
Serum zinc concentrations are reduced during acute infections and inflammation [86]. Corbo et 
al. point out that acute stress and inflammation may contribute to zinc redistribution, leading to 
lower plasma zinc concentrations without affecting total body store [87]. Conversely, normal serum 
levels do not necessarily translate to a sufficient body store of zinc. Zinc deficiency causes thymic 
atrophy, lymphopenia, and compromised cell- and antibody-mediated responses that increase the 
rates and duration of infections. Zinc deficiency is characterized by decreased lymphocyte number 
and function, particularly T cells, increased thymic atrophy, altered cytokine production that 
contributes to oxidative stress and inflammation [65]; increased risk of bacterial, viral, and fungal 
infections (particularly diarrhea and pneumonia) [88] and diarrheal and respiratory morbidity 
[66,89]. Contrariwise, its supplementation produces the restoration of thymulin activity, increased 
numbers of cytotoxic T cells, reduced numbers of activated T helper cells (which can contribute to 
autoimmunity), increased natural killer cell cytotoxicity, and reduced incidence of infections [65]. In 
children, there is a reduction in the duration of diarrhoea and incidence of pneumonia in at-risk 
children >6 month, but not in children 2–6 month [88]; reduced duration and severity of common 
cold symptoms; and, improved outcomes in pneumonia, malaria, and diarrheal symptoms [67,90]. 
In the airway epithelium, zinc is important for ciliary function, wound healing, and 
suppression of oxidative stress and apoptosis; all of which have been shown to be impaired in CF. 
Zinc is known to play a regulatory role in the immune system where correlations have been found 
between plasma zinc and IL-2 levels, natural killer cell activity, and active thymulin in CF children. 
Zinc status also affects the expression of proinflammatory cytokines, such as TNFα, IL-1β, and IL-8 
[38]. Zinc deficiency leads to an increase in oxidative damage in the airways by causing infiltration 
of inflammatory cells and increases the production of nitric oxide and superoxide. When this 
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deficiency occurs in conjunction with acute damage to the lung or asthma, greater inflammation 
occurs, increasing the frequencies of hospitalizations [73]. According to Ataee et al., the number of 
hospitalizations was significantly reduced after zinc administration, which could be due to the 
preventive effect of zinc on pneumonia, which is a major cause of hospitalization in these patients 
{33]. Zinc, an acute phase reactant, would shorten the duration of severe pneumonia and time in the 
hospital. Adjuvant treatment with 20 mg zinc per day accelerated recovery from severe pneumonia 
in children and could help to reduce antimicrobial resistance by decreasing multiple antibiotic 
exposures and lessen complications and deaths where second-line drugs are unavailable [91]. 
Even though data on zinc supplementation among children with cystic fibrosis are limited 
[33,57,73,92,93], the ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and 
adult with CF suggest zinc supplementation for people who are at risk of zinc insufficiency [1]. At 
present, despite contradictory findings, many researchers believe that the intake of 30 mg/day of 
zinc reduces the number of days of antibiotics used to treat respiratory tract infections in these 
children [73]. The supplementation trial in 13 Swedish children (2–19 years) for six months 
demonstrated the transient normalization of plasma zinc levels, where all subjects had had low 
plasma zinc levels at baseline, but growth velocity or lung function did not improve with the 
normalization of plasma zinc levels [93]. However, Borowitz et al. reported that empiric zinc 
supplementation as a treatment trial for a period of six months can be considered for CF patients 
who are failing to thrive or that have short stature [55].  
In spite of the fact that Sharma et al. in a double-blind randomized placebo-controlled, the 
study of zinc supplementation in 37 children with CF (age 5–15 y) did not find any significant 
difference in the need for antibiotics, pulmonary function tests, hospitalization, colonization with 
pseudomonas, or the need for antibiotics. They highlighted that the majority of the children had low 
serum zinc levels at baseline; therefore, the dose of zinc administered may not have been sufficient 
to have an impact on the outcomes [92]. Conversely, Abdulhamid et al. conducted a double-blind 
randomized controlled small trial in which 26 children were treated with placebo or zinc (30 
mg/day) for one year. They documented that the requirement for antibiotics was significantly lower 
among those receiving zinc than those receiving placebo (p = 0.05). The improvement was more 
pronounced among those who had low plasma zinc at baseline (p = 0.02). Reduced levels of plasma 
interleukin-6 and interleukin-8 were also documented. Furthermore, they recommended that higher 
daily doses of zinc might be necessary to decrease respiratory tract infections and modify the 
immune response [73].  
WHO/UNICEF/IAEA/IZiNCG recommends that if more than 20% of the population (or 
population sub-group) has SZC below the relevant cut-off, more than 25% has inadequate dietary 
zinc intake below the EAR and more than 20% of children less than five years old who are stunted, 
the whole population (or sub-group) should be considered to be at risk of zinc deficiency and of 
public health concern, and an intervention to improve population zinc status is recommended 
[32,78]. At that point, in the present study, we have considered four highlights. Firstly, the median 
SZC was normal (88 μg/dL) [31] but the median dietary zinc intake (98%DRI) was lower from 
European recommendations for zinc and presented a significant difference from the NHANES II 
control group (p < 0.00) [68]. Secondly, no patient less than five years had stunted growth. Thirdly, 
the patients with hypozincemia (zone of risk > 20%) and dietary zinc deficiency (zone of risk > 25%) 
were close to the zone of high risk of zinc deficiency [32,78]. Finally, in spite of the fact that 23.5% of 
patients had inadequate dietary zinc intake, none of them had hypozincemia (17.6%).  
Taking all highlights into account, we should indicate that this situation of patients with 
inadequate dietary zinc without hypozincemia should alert us to a state of marginal zinc deficiency, 
which may explain why there were no overlapping cases between the two groups. Consequently, we 
suggest that approximately 41% (7/17 cases) of patients with CF (patients with serum zinc deficiency 
and dietary zinc intake) would be at high risk of zinc deficiency, and that an intervention 
strategy—dietary modification/diversification, supplementation, fortification, and 
bio-fortification—should be carried out about these patients with CF.  
Nutrients 2019, 11, 150 14 of 18 
 
One limitation of the study is its small sample size, while its strengths include the 
determination of the nutritional status of zinc by the percentage of cases with hypozincemia, stunted 
growth in children less than five years, and inadequate intake of zinc in the diet. By design, this 
study focused on patients with CF with or without IR and IP. There is a need for large multicentric 
trials to improve the understanding of the nutritional status of zinc in these patients and to 
determine the amount needed and adequate zinc supplementation to improve the nutritional status 
with cystic fibrosis; we suggest conducting a multicentre international study and changing the 
approach to include the risk of zinc deficiency in health primary prevention. 
5. Conclusions 
Serum zinc was associated with nutritional status, expressed as BMI and weight-for-height 
Z-score. Moreover, dietary zinc intake was associated with nutritional status expressed as energy 
intake and weight-for-height Z-score. In the series, 23.5% (4/17) of patients with CF had inadequate 
dietary zinc intake and 17.6% (3/17) had hypozincemia. No patients with zinc deficient intake had 
hypozincemia. This situation of deficient dietary zinc intake without hypozincemia should alert us 
to a state of marginal deficiency of zinc. Therefore, we suggest that it should be considered that the 
percentage of patients with a deficient status of zinc could be much higher, and about 41% of our 
patients with CF would be at high risk of zinc deficiency and a zinc supplementation may be 
considered. 
 
Figure 5. Relationship between dietary zinc intake and weight-for-height Z-score. 
%DRI: Percentage of Dietary Reference Intake. 
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